Claims for Patent: 5,783,425

Summary for Patent: 5,783,425

Title:	Amino and peptido modified enzymatic nucleic acid
Abstract:	An enzymatic nucleic acid molecule, comprising a moiety having the formula: ##STR1## wherein B is a nucleotide base or hydrogen; R is selected from the group consisting of aminoacyl group, and NHR.sub.4 group, wherein said R.sub.4 is independently selected from the group consisting of a peptidyl group containing between 2 and 5 amino acids inclusive, and CO--CR.sub.1 R.sub.2 R.sub.3, wherein R.sub.1, R.sub.2 and R.sub.3 independently is selected from the group consisting of hydrogen, an alkyl group containing between 2 and 10 carbon atoms inclusive, and an alkyl amine; and the zigzag lines are independently hydrogen or a bond.
Inventor(s):	Dudycz; Lech (Worcester, MA), Matulic-Adamic; Jasenka (Boulder, CO), Beigelman; Leonid (Longmont, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	08/357,577
Patent Claims:	1. An enzymatic nucleic acid molecule, comprising a moiety having the formula: ##STR3## wherein B is a nucleotide base or hydrogen; R is selected from the group consisting of aminoacyl group, and NHR.sub.4 group, wherein said R.sub.4 is independently selected from the group consisting of a peptidyl group containing between 2 and 5 amino acids inclusive, and CO--CR.sub.1 R.sub.2 R.sub.3, wherein R.sub.1, R.sub.2 and R.sub.3 independently is selected from the group consisting of hydrogen, an alkyl group containing between 2 and 10 carbon atoms inclusive, and an alkyl amine; and the zigzag lines are independently hydrogen or a bond. 2. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hammerhead motif. 3. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a, hepatitis delta virus, group I intron, VS RNA or RNase P RNA motif. 4. The enzymatic nucleic acid molecule of claim 2, wherein said hammerhead motif has a nucleotide position 4 and a nucleotide position 7, wherein the 2'-position of the sugar moiety of said position 4 and said position 7 are individually or in combination substituted with a aminoacyl group. 5. A mammalian cell comprising an enzymatic nucleic acid molecule of any one of claims 1-4 in vitro. 6. The mammalian cell of claim 5, wherein said mammalian cell is a human cell. 7. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hairpin motif. 8. The enzymatic nucleic acid molecule of claim 2, wherein the 2'-position of at least one of the sugar moieties of said enzymatic nucleic acid molecule is modified with an aminoacyl group. 9. The enzymatic nucleic acid molecule of claim 4, wherein the 2'-position of at least one of the sugar moieties of said enzymatic nucleic acid molecule is modified with a an aminoacyl group. 10. The enzymatic nucleic acid molecule of claim 4, wherein the 2'-position of the sugar moiety of said position 4 is substituted with a --NH-lysyl group. 11. The enzymatic nucleic acid molecule of claim 4, wherein the 2'-position of the sugar moiety of said position 7 is substituted with a --NH-lysyl group. 12. The enzymatic nucleic acid molecule of claim 4, wherein the 2'-position of the sugar moiety of said position 4 and said position 7 is substituted with a --NH-lysyl group. 13. The enzymatic nucleic acid molecule of claim 4, wherein the 2'-position of the sugar moiety of said position 4 is substituted with a --NH-alanyl group. 14. The enzymatic nucleic acid molecule of claim 4, wherein the 2'-position of the sugar moiety of said position 7 is substituted with a --NH-alanyl group. 15. The enzymatic nucleic acid molecule of claim 4, wherein the 2'-position of the sugar moiety of said position 4 and said position 7 is substituted with an --NH-alanyl group. 16. The enzymatic nucleic acid molecule of claim 2, wherein 2'-positions of at least two of the sugar moieties of said enzymatic nucleic acid molecule is modified with an aminoacyl group, wherein said aminoacyl groups are same or different.

Details for Patent 5,783,425

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-07-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-07-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-07-21